HUE037586T2 - Prolaktin receptor kötõ proteinek és alkalmazásaik - Google Patents

Prolaktin receptor kötõ proteinek és alkalmazásaik

Info

Publication number
HUE037586T2
HUE037586T2 HUE13821368A HUE13821368A HUE037586T2 HU E037586 T2 HUE037586 T2 HU E037586T2 HU E13821368 A HUE13821368 A HU E13821368A HU E13821368 A HUE13821368 A HU E13821368A HU E037586 T2 HUE037586 T2 HU E037586T2
Authority
HU
Hungary
Prior art keywords
binding proteins
receptor binding
prolactin receptor
prolactin
proteins
Prior art date
Application number
HUE13821368A
Other languages
English (en)
Inventor
Mark Anderson
Jieyi Wang
Archana Thakur
Debra Chao
Chung-Ming Hsieh
Qian Zhang
Edward Reilly
Enrico Digiammarino
Kenton Longenecker
Russell Judge
David Egan
Charles Hutchins
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE037586T2 publication Critical patent/HUE037586T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/86Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
    • G01S13/867Combination of radar systems with cameras
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/88Radar or analogous systems specially adapted for specific applications
    • G01S13/91Radar or analogous systems specially adapted for specific applications for traffic control
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/50Context or environment of the image
    • G06V20/56Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
    • G06V20/58Recognition of moving objects or obstacles, e.g. vehicles or pedestrians; Recognition of traffic objects, e.g. traffic signs, traffic lights or roads
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/0104Measuring and analyzing of parameters relative to traffic conditions
    • G08G1/0125Traffic data processing
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/015Detecting movement of traffic to be counted or controlled with provision for distinguishing between two or more types of vehicles, e.g. between motor-cars and cycles
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/04Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/042Detecting movement of traffic to be counted or controlled using inductive or magnetic detectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Remote Sensing (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Multimedia (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13821368A 2012-12-24 2013-12-23 Prolaktin receptor kötõ proteinek és alkalmazásaik HUE037586T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261745707P 2012-12-24 2012-12-24

Publications (1)

Publication Number Publication Date
HUE037586T2 true HUE037586T2 (hu) 2018-09-28

Family

ID=49956483

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13821368A HUE037586T2 (hu) 2012-12-24 2013-12-23 Prolaktin receptor kötõ proteinek és alkalmazásaik

Country Status (29)

Country Link
US (4) US9725515B2 (hu)
EP (2) EP3363817A1 (hu)
JP (3) JP6382221B2 (hu)
KR (1) KR20150100881A (hu)
CN (1) CN105102480B (hu)
AU (3) AU2013370548B2 (hu)
BR (1) BR112015015289A2 (hu)
CA (1) CA2896058A1 (hu)
CY (1) CY1120286T1 (hu)
DK (1) DK2935331T3 (hu)
ES (1) ES2671506T3 (hu)
HK (1) HK1216257A1 (hu)
HR (1) HRP20180822T1 (hu)
HU (1) HUE037586T2 (hu)
IL (1) IL239502B (hu)
LT (1) LT2935331T (hu)
ME (1) ME03075B (hu)
MX (1) MX359532B (hu)
NO (1) NO2968312T3 (hu)
PL (1) PL2935331T3 (hu)
PT (1) PT2935331T (hu)
RS (1) RS57259B1 (hu)
RU (2) RU2018129572A (hu)
SG (1) SG11201504943QA (hu)
SI (1) SI2935331T1 (hu)
TR (1) TR201807416T4 (hu)
TW (3) TWI646106B (hu)
WO (1) WO2014105810A1 (hu)
ZA (1) ZA201504803B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
HUE037586T2 (hu) 2012-12-24 2018-09-28 Abbvie Inc Prolaktin receptor kötõ proteinek és alkalmazásaik
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
AR098221A1 (es) 2013-11-04 2016-05-18 Pfizer Conjugados de anticuerpo anti-efna4-fármaco
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
CA2990565A1 (en) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf and anti-human transferrin receptor antibody
AU2016283343B2 (en) * 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
IL258768B2 (en) * 2015-11-12 2023-11-01 Siamab Therapeutics Inc Compounds interacting with glycans and methods of use
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN106265480A (zh) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 纳米抗体***给药***及制备方法和应用
SG10201914120XA (en) 2016-09-14 2020-03-30 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies
JP7330101B2 (ja) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス,インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2017366873A1 (en) * 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2019007719A (es) 2016-12-26 2019-09-09 Japan Chem Res Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefalica.
KR102471458B1 (ko) * 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
AU2018237549A1 (en) * 2017-03-20 2019-08-01 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗-prlr抗體藥物軛合物(adc)及其用途
EP3612625A4 (en) 2017-04-21 2021-08-18 Mellitus, LLC PROCEDURE AND ANTIBODIES FOR DIABETES ASSOCIATED APPLICATIONS
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
WO2018213592A1 (en) * 2017-05-19 2018-11-22 J. Craig Venter Institute Compositions and methods for resolution of inflammation
JP7299160B2 (ja) * 2017-08-03 2023-06-27 アレクトル エルエルシー 抗cd33抗体及びその使用方法
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
WO2020028428A2 (en) * 2018-07-31 2020-02-06 Pdi Therapeutics, Inc. Anti-mica/b antibodies that block mica/b shedding and methods of use
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3992209A4 (en) * 2019-07-12 2023-01-18 Futuregen Biopharmaceutical (Beijing) Co., Ltd. CLDN18.2 ANTIBODY AND ITS USE
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
EP4037711A4 (en) 2019-10-03 2024-02-14 Atyr Pharma Inc COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
KR20230003580A (ko) * 2020-04-30 2023-01-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-cd79b 항체 및 키메라 항원 수용체 및 이의 사용 방법
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022266539A2 (en) * 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
AU2022375785A1 (en) * 2021-10-27 2024-04-11 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN115353541B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 ***衍生物的制备方法,中间体、其制备方法和应用
CN115417908B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 ***衍生物、其制备方法、检测试剂盒及***定量检测方法
CN117694469B (zh) * 2024-02-02 2024-04-23 潍坊新希望六和饲料科技有限公司 一种改善褐壳鸡蛋蛋壳质量的饲料添加剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867187B2 (en) 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
US7507716B2 (en) 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
GEP20125612B (en) * 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
KR101672401B1 (ko) 2009-02-26 2016-11-16 온코릭스, 아이엔씨. 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011151405A1 (en) 2010-06-04 2011-12-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
HUE037586T2 (hu) 2012-12-24 2018-09-28 Abbvie Inc Prolaktin receptor kötõ proteinek és alkalmazásaik
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use

Also Published As

Publication number Publication date
AU2021202954A1 (en) 2021-06-03
SG11201504943QA (en) 2015-07-30
AU2019202725A1 (en) 2019-05-16
RU2015130605A (ru) 2017-01-24
ZA201504803B (en) 2020-02-26
US10184003B2 (en) 2019-01-22
US20140227294A1 (en) 2014-08-14
LT2935331T (lt) 2018-06-25
US20170022281A1 (en) 2017-01-26
BR112015015289A2 (pt) 2017-08-15
NO2968312T3 (hu) 2018-06-30
SI2935331T1 (en) 2018-06-29
EP3363817A1 (en) 2018-08-22
PL2935331T3 (pl) 2018-07-31
PT2935331T (pt) 2018-06-04
TR201807416T4 (tr) 2018-06-21
EP2935331A1 (en) 2015-10-28
JP2016504035A (ja) 2016-02-12
MX2015008299A (es) 2016-02-11
RU2018129572A (ru) 2018-10-12
US20210312797A9 (en) 2021-10-07
CN105102480B (zh) 2019-04-16
ME03075B (me) 2019-01-20
RU2664463C2 (ru) 2018-08-17
AU2013370548B2 (en) 2019-01-17
JP2020188775A (ja) 2020-11-26
IL239502A0 (en) 2015-08-31
TW201920283A (zh) 2019-06-01
RS57259B1 (sr) 2018-08-31
HK1216257A1 (zh) 2016-10-28
IL239502B (en) 2019-11-28
EP2935331B1 (en) 2018-02-28
TWI646106B (zh) 2019-01-01
US20210074147A1 (en) 2021-03-11
JP2018198608A (ja) 2018-12-20
AU2013370548A1 (en) 2015-07-09
CA2896058A1 (en) 2014-07-03
DK2935331T3 (en) 2018-06-06
TW201441259A (zh) 2014-11-01
KR20150100881A (ko) 2015-09-02
MX359532B (es) 2018-10-01
ES2671506T3 (es) 2018-06-06
JP6382221B2 (ja) 2018-08-29
TW201920245A (zh) 2019-06-01
US9725515B2 (en) 2017-08-08
US20190153110A1 (en) 2019-05-23
HRP20180822T1 (hr) 2018-08-10
CY1120286T1 (el) 2019-07-10
WO2014105810A1 (en) 2014-07-03
CN105102480A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
HK1216257A1 (zh) 催乳素受體結合蛋白及其用途
HK1205136A1 (en) Cdim binding proteins and uses thereof cdim
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
HK1198832A1 (en) Fn14 binding proteins and uses thereof fn14
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP2558500A4 (en) PI16 BINDING PROTEINS AND THEIR USE
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
EP2817324A4 (en) NEMO BOND DOMAIN FUSION PROTEINS
GB201208372D0 (en) Antibodies and uses thereof
GB201203944D0 (en) Binding polypeptides